Valproic Acid Capsule, Liquid Filled
Product Images NDC 17856-0152

4 FDA label images from Atlantic Biologicals Corp. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Valproic Acid (NDC 17856-0152). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (17856 0152 01)

Image Description (17856 0152 01)
Label for Valproic Acid 250 mg capsules by Atlantic Biologicals Corp. The label includes storage instructions to keep capsules between 15 to 25°C (59 to 77°F), protect gelatin capsules from moisture and humidity, and a warning to keep medication out of reach of children. It indicates a quantity of 100 capsules with an expiration date of 12/22/21 and packaging details from Unit Dose Solutions, Morristown, NC, and distributor Atlantic Biologicals Corp. Miami FL.*
FDA Label Image

Undefined (Image 00001)

Undefined (Image 00001)
Chemical structure of Valproic Acid displayed as a structural formula showing carbon (CH3, CH2, CH) and functional groups including a carboxyl group (COOH).*
FDA Label Image

Undefined (Image 00002)

Undefined (Image 00002)
A chart showing percentage reduction in CPS rate versus percentage of patients for two groups: Depakote and Placebo. The y-axis displays percentage reduction in CPS rate from -100% to 100%, indicating worsening, no change, or improvement. The x-axis shows percentage of patients from 100 to 0. The chart compares the performance of Depakote and Placebo on CPS rate reduction.*
FDA Label Image

Undefined (Image 00003)

Undefined (Image 00003)
A line graph showing the percentage reduction in CPS rate on the vertical axis against the percentage of patients on the horizontal axis. Two lines compare outcomes for High Dose (solid line) and Low Dose (dotted line) treatments. The graph indicates changes from worsening to improvement across patients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.